Armistice Capital’s Achieve Life Sciences ACHV Stock Holding History

Armistice Capital’s Portfolio ACHV Stock Details ACHV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-22,400	Closed	-$542K	–	71
2018 Q4	$542K	Buy	+22,400	New	+$845K	0.04%	63
2018 Q3	–	Sell	-3,100	Closed	-$234K	–	78
2018 Q2	$234K	Buy	+3,100	New	+$632K	0.02%	72

Other funds holding ACHV

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Searle & Co Greenwich, Connecticut $445M AUM 41.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Armistice Capital's ACHV Position: Q1 2019 in Review

Armistice Capital sold out of Achieve Life Sciences (ACHV) in Q1 2019, closing a stake of 22,400 shares — an estimated $542K sold.

Armistice Capital first reported a position in ACHV in Q2 2018 and held it in 2 quarters. The position peaked at $542K in Q4 2018. 15 funds tracked by Wall St. Rank hold ACHV as of Q1 2019.

Armistice Capital reported no remaining Achieve Life Sciences position as of Q1 2019 after selling out during the quarter.
Armistice Capital sold 22,400 Achieve Life Sciences shares in Q1 2019, an estimated $542K.
Armistice Capital first reported a position in Achieve Life Sciences in Q2 2018 and held it in 2 quarters.
Armistice Capital's Achieve Life Sciences position peaked at $542K in Q4 2018.
15 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q1 2019.

Based on Armistice Capital's 13F filing for Q1 2019, filed 15 May 2019.